ZURICH, SWITZERLAND – DEC 13, 2019 –Syntropy Asset Mgmt, is today commencing its tender offer for all 500,000,000 shares of Second Round financing of Common Stock of HKY Biotech Inc., Hong Kong, at a price of US$5.00 per share, payable in cash. The offer, which has been unanimously approved and recommended by HKY Biotech’s Board of Directors is being made pursuant to the agreement between the two companies.                                                                   

The tender offer, which is currently scheduled to expired at 12:00 midnight EST on Friday, January 10th, 2020 (unless extended) is subject to the tender by HKY Biotech’s shareholders and would represent a majority of the outstanding shares on a fully diluted basis, as well as other customary conditions.                                                           

HKY Biotech Inc. aims to become a leader in advanced drug delivery systems with Graphine Oxide being the key component. After extensive research and testing the firm’s proprietary protocols are now nearing completion of initial phase clinical trials in Hong Kong. Ken Holland, Head of Corporate Affairs for HKY Biotech said, “When completed, this tender offer provides the company with substantial cash reserves allowing for continued product development. Institutional sponsorship is critical to strengthening our market position for the long term.”

With over 35 years of experience in mergers and acquisitions and corporate advisory, Syntropy Asset Mgmt Director of Bio-Pharm Transactional Services, Mr. Craig Kirkman, will be heading the project and is confident of a speedy, successful outcome given HKY Biotech’s technology and positioning in the bio-tech sector, commenting “HKY Biotech’s potential life extending technology is a potential ‘super generic’ with far superior effectiveness over conventional cancer treatments.”

About Syntropy Asset Mgmt

Syntropy Asset Mgmt is a global corporate advisory with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, groups and individuals worldwide with its headquarters located in Hong Kong and Switzerland. Independent advice and intellectual rigor are hallmarks of our commitment to client success across our advisory services.

HKY Biotech, Inc.

HKY Biotech, Inc. is an independent biotech firm based in Hong Kong with a focus on the research and development of Nano-particle, bio-therapeutic drug delivery systems for the treatment of cancerous tumors, in particular lung cancer. The firm’s core objective is to deliver highly innovative cancer therapies that currently have few, if any, effective treatment options. 

For further information, please contact:

(Client Advisory Services)

Syntropy Asset Mgmt

Chamestr, 172,

6300 Zug


Tel: +41 22 544 54 68

Email: [email protected] 


Mel Currie (International Investor Relations)
HKY Biotech

Leopont Centre

18-28 Wo Liu Hang Road

Shatin, Hong Kong

Tel: +852 580 32509

Email: [email protected] 


Media Contact
Company Name: Syntropy Asset Mgmt
Contact Person: Media Relations
Email: Send Email
Phone: +41 22 544 54 68
Address:Chamestr, 172
City: 6300 Zug
Country: Switzerland